2014-02-27 00:08:02 - Diabetes Treatments: World Drug Market 2013-2023 - a new market research report on companiesandmarkets.com
The global diabetes medications market will reach $55.3bn in 2017. Human insulins and analogues dominated the antidiabetics market in 2012. Furthermore, that submarket will maintain dominance in the overall diabetes treatments market to 2023. Also, rapid uptake of dipeptidyl peptidase (DPP)-4 inhibitors will stimulate overall revenue growth, owing to their safety profiles and once-daily dosage regimens. The overall diabetes drugs market will thus achieve strong growth to 2013, especially from 2013 to 2017. Its future is promising, based on existing drugs and agents under development. It has strong, broad-ranging R&D.
An increase in the worldwide incidence of type 1 and type 2 diabetes, coupled with increases in obesity, will stimulate growth of the diabetes drugs market. In addition, the market will
increase in competition, as the development of type 1 and type 2 diabetes treatments remains profitable for pharmaceutical companies in the short and long term. Also, with companies entering the market from 2013, it is predicted that the market will see more collaborations and alliances. In addition, the diabetes treatment industry and market will encourage combination therapy, with drugs developed as a monotherapy finding it harder in future to gain market share.
The incidence of diabetes will surge owing to rising levels of obesity and sedentary lifestyles in the global population. Those trends are most evident in emerging countries, such as China and India, which are expected to account for much of the growth of the treatment market. Also, as companies set up operations and facilities in developing countries, to harness the growing patient pool, this increases market competition. That trend helps stimulate innovation and price reductions, an incentive for less-affluent patients in developing countries.
Furthermore, the diabetes drug market has a strong R&D pipeline. Also, there´s need for new antidiabetic treatments with improved efficacy and safety. In addition, as obesity is closely related to type 2 diabetes, medications that target long-term weight reduction and other related conditions are in high demand. Indeed, owing to the multifactorial aspects of diabetes, drug manufacturers developing medications for associated complications â obesity, heart disease, kidney disease or stroke â are evaluating medicines in clinical trials for treating diabetes. That expanded use of antidiabetics will offer drug manufacturers opportunities to tackle multiple aspects of metabolic disorders and to market drugs to a larger target population, increasing revenues and profits, as well as benefiting patients and healthcare providers. Worldwide, the diabetes drugs market retains great potential for increasing revenues, through technological and commercial progress.
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.